- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04947826
Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis
A Randomized, Double-blinded, Controlled Phase II Study of Combination Therapy of HAIC (Hepatic Arterial Infusion Chemotherapy), HLX10 (PD-1 Antibody) and HLX04 (VEGF Antibody) Compared With HAIC and Placebo in Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis
Study Overview
Status
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing to attend the study and having given the ICF
- Age ≥18
- Have a HCC diagnosis confirmed by radiology, histology, or cytology
- HCC is diagnosed at Barcelona Clinic Liver Cancer (BCLC) Stage C with major portal vein tumor thrombosis ( VP3~4, or Cheng's II~IV)
- Have not accepted any of systemic therapy for HCC such as systemic chemotherapy, molecular targeted drugs, immunotherapy.
- At least 1 measurable intrahepatic lesion suitable for repeat assessments according to RECISTv1.1 criteria and it has not undergone surgery, radiology and/or other regional therapy (including but not limited to radiofrequency ablation, percutaneous ethanol injection, freezing therapy, high intensity focused ultrasound, transcatheter arterial chemoembolization, transcatheter arterial embolization). But if it progressed after the regional therapy, it could be selected as a target lesion. The local regional therapy must be done 4 weeks before randomization and the related AEs must recover to ≤ CTCAE grade 1.
- Child-Pugh score ≤7
- Eastern Cooperative Oncology Group (ECOG) 0 or 1
- Expected life time is over 12 weeks.
- HBV-DNA < 2000 IU/mL
- Organs function:
Platelet count ≥75×109/L Absolute neutrophil count (ANC) ≥1.5×109 /L White blood cell count ≥3.0×109 /L Haemoglobin ≥9.0 g/dL Serum total bilirubin ≤1.5×ULN ALT ≤5×ULN, and AST ≤5×ULN(ALT ≤3×ULN, and AST ≤3×ULN, if HCV-RNA is detectable) Albumin ≥28 g/L INR ≤1.5×ULN PT ≤1.5×ULN APTT ≤1.5×ULN Creatinine clearance (CL) >50 mL/min or serum creatinine ≤1.5×ULN Urine protein ≤1+ or ≤1.0g/24h 12. Patient is not fertile or willing and able to obey effective contraception.
Exclusion Criteria:
- Known fibrolamellar HCC, sarcomatoid HCC, mixed cholangiocarcinoma and HCC
- History of hepatic encephalopathy
- History of GI bleeding within 6 months, or investigator defined with high risk of haemorrhage for esophageal varices
- With distant metastasis (hilar lymph nodes metastasis is allowed)
- Co-infection of HBV and HCV
- History of other malignancy within 5 years except for healed local tumor.
- History of or plan to accept allogenic organ transplantation
- Ascites requiring invasive intervention (e.g. paracentesis) to maintain symptomatic control (every month or more often)
- History of myocardial infarction or unstable angina or uncontrolled arrythmia or stroke or cerebral hemorrhage within 6 months prior to randomization. QTcF value ≥450ms(male)or ≥470ms(female) detected by 12-lead electrocardiogram.
- New York Heart Association Grade ≥2 congestive heart failure or LVEF <50%
- Uncontrolled hypertension
- History of hypertensive crisis or hypertensive encephalopathy
- Active infection including but not limited to tuberculosis and HIV
- With interstitial lung disease, lung fibrosis, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia and serious impairment in lung function
- Active autoimmune disorders except patients with substitutional treatment with thyroid hormone and type I diabetes under treatment with insulin.
- Receipt of live attenuated vaccine within 28 days prior to randomization
- Current or prior use of steroids (>10mg/d prednisone) or immunosuppressive medication within 14 days before randomization
- Significant traumatic injury or major surgical procedure within 28 days prior to randomization
- Receipt of checkpoint inhibitors or T cell costimulatory drugs
- Receipt of bevacizumab or its analogues
- Involved in another clinical trial less than 14 days before randomization
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control
- Active bleeding, with history of ≥grade 3 bleeding within 6 months, or ≥grade 2 bleeding within 3 months
- Use of anti-thrombotics within 5 days prior to randomization
- In need of NSAIDs for long-term treatment.
- With one of the following diseases within 6 months before randomization:
(1) Digestive fistula, perforation and abscess (2) Gastrointestinal obstruction (3) Abdominal infection or inflammation (4) Major vascular disease 28. With severe and green wound, active ulcer or untreated fracture 29. History of drug abuse 30. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to screen for the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HAIC + HLX10 + HLX04
HAIC: FOLFOX, q3w, up to 8 times; HLX10: 4.5mg/kg, iv, q3w, up to 2 years; HLX04: 15.0mg/kg, iv, q3w, up to 2 years.
|
For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery.
Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed.
According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver.
The catheter or microcatheter was connected to an external infusion pump.
The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours.
After HAIC treatment, the catheter or microcatheter, and the sheath were removed.
PD-1 antibody with proven efficacy in advanced hepatocellular carcinoma
Combination of PD-1 antibody and VEGF antibody might promote the efficacy of HAIC in hepatocellular carcinoma with major portal vein thrombosis.
|
Placebo Comparator: HAIC + Placebo
HAIC: FOLFOX, q3w, up to 8 times; Placebo1: saline, iv, q3w, up to 2 years; Placebo2: saline, iv, q3w, up to 2 years.
|
Placebo
For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery.
Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed.
According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver.
The catheter or microcatheter was connected to an external infusion pump.
The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours.
After HAIC treatment, the catheter or microcatheter, and the sheath were removed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: The proportion of patients with complete response or partial response, through study completion, an average of 3 years.
|
efficacy
|
The proportion of patients with complete response or partial response, through study completion, an average of 3 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, up to 48 months
|
efficacy
|
From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, up to 48 months
|
Duration of response
Time Frame: From date of randomization until the date of first documented progression, up to 48 months
|
efficacy
|
From date of randomization until the date of first documented progression, up to 48 months
|
Time to response
Time Frame: From date of randomization until the date of first documented response, up to 48 months
|
efficacy
|
From date of randomization until the date of first documented response, up to 48 months
|
Time to progression
Time Frame: From date of randomization until the date of first documented progression, up to 48 months
|
efficacy
|
From date of randomization until the date of first documented progression, up to 48 months
|
Overall survival
Time Frame: From date of randomization until death from any cause, up to 48 months
|
efficacy
|
From date of randomization until death from any cause, up to 48 months
|
Progression free survival rate at 12-month time point
Time Frame: From date of randomization until 12-month time point
|
efficacy
|
From date of randomization until 12-month time point
|
Overall survival rate at 12-month time point
Time Frame: From date of randomization until 12-month time point
|
efficacy
|
From date of randomization until 12-month time point
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate according to iRECIST criteria
Time Frame: The proportion of patients with complete response or partial response according to iRECIST criteria, through study completion, an average of 3 years.
|
efficacy
|
The proportion of patients with complete response or partial response according to iRECIST criteria, through study completion, an average of 3 years.
|
Progression free survival according to iRECIST criteria
Time Frame: From date of randomization until date of confirmed progression according to iRECIST criteria, up to 48 months
|
efficacy
|
From date of randomization until date of confirmed progression according to iRECIST criteria, up to 48 months
|
Duration of response according to iRECIST criteria
Time Frame: From date of randomization until date of confirmed progression according to iRECIST criteria, up to 48 months
|
efficacy
|
From date of randomization until date of confirmed progression according to iRECIST criteria, up to 48 months
|
Time to response according to iRECIST criteria
Time Frame: From date of randomization until date of the first documented response according to iRECIST criteria, up to 48 months
|
efficacy
|
From date of randomization until date of the first documented response according to iRECIST criteria, up to 48 months
|
Time to progression according to iRECIST criteria
Time Frame: From date of randomization until date of confirmed progression according to iRECIST criteria, up to 48 months.
|
efficacy
|
From date of randomization until date of confirmed progression according to iRECIST criteria, up to 48 months.
|
Adverse events rate
Time Frame: From date of randomization until 30 days after the last treatment or beginning of new anti-cancer therapy, whichever comes first, up to 48 months
|
Safety
|
From date of randomization until 30 days after the last treatment or beginning of new anti-cancer therapy, whichever comes first, up to 48 months
|
Severe adverse events rate
Time Frame: From date of randomization until 90 days after the last treatment, up to 48 months
|
Safety
|
From date of randomization until 90 days after the last treatment, up to 48 months
|
Discontinuation rate due to any adverse events
Time Frame: From date of randomization until the last treatment, up to 48 months
|
Safety
|
From date of randomization until the last treatment, up to 48 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Embolism and Thrombosis
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Thrombosis
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Immunoglobulins
Other Study ID Numbers
- HHH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma With Major Portal Vein Thrombosis
-
Hospital Sirio-LibanesTerminatedHepatocellular Carcinoma | Hepatic Portal Vein Tumor Invasion | Portal Vein ThrombosisBrazil
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnHepatocellular Carcinoma With Portal Vein ThrombosisIndia
-
Peking UniversityRecruitingHepatocellular Carcinoma | Portal Vein ThrombosisChina
-
Shanghai Zhongshan HospitalNot yet recruitingHepatocellular Carcinoma With Portal Vein Tumor ThrombusChina
-
Sun Yat-sen UniversityGuangzhou 8th People's Hospital; Kaiping Central Hospital; The 458 Hospital of...TerminatedHepatocellular Carcinoma With Portal Vein Tumor ThrombusChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingPortal Vein Thrombosis | Primary Hepatocellular Carcinoma
-
Beijing Tsinghua Chang Gung HospitalUnknownHepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)China
-
Peking UniversityCompletedPortal Vein Thrombosis | HepatoCellular CarcinomaChina
-
First Affiliated Hospital of Zhejiang UniversityRecruitingUnresectable Hepatocellular Carcinoma | Portal Vein ThrombosisChina
-
Taiwan Liposome CompanyTerminatedHepatoCellular Carcinoma | Portal Vein Tumor ThrombosisTaiwan
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States